SCHEMBL23540929

SCHEMBL23540929

Cn1c(=O)n(-c2ccc(OCc3ccccc3)nc2OCc2ccccc2)c2ccc(-c3ccc(CC(=O)O)cc3F)cc21

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 0.40
▸ SOAT1 P35610 2/20 0.40
▸ RXRA P19793 2/20 0.36
▸ RXRB P28702 2/20 0.36
▸ RXRG P48443 1/20 0.36
▸ PTGDR2 Q9Y5Y4 4/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.36
▸ FEN1 P39748 1/20 0.35
▸ PKM P14618 1/20 0.34
▸ FAAH O00519 1/20 0.34
▸ PTGS2 P35354 1/20 0.34
▸ PPARD Q03181 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ GRM5 P41594 1/20 0.34
▸ PTGER4 P35408 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30026709 1.00 DGAT1 (0.40) DGAT1SOAT1RXRARXRBRXRG
SCHEMBL23541326 0.91 GRM5 (0.33) DGAT1SOAT1RXRARXRBRXRG
SCHEMBL30027013 0.91 GRM5 (0.33) DGAT1SOAT1RXRARXRBRXRG
SCHEMBL31397143 0.91 DGAT1 (0.39) DGAT1SOAT1RXRARXRBRXRG
SCHEMBL23553200 0.90 PTGDR2 (0.33) DGAT1SOAT1PTGDR2FFAR4FEN1
SCHEMBL31397211 0.90 DGAT1 (0.39) DGAT1SOAT1RXRARXRBRXRG
SCHEMBL24819487 0.89 RXRA (0.39) DGAT1SOAT1RXRARXRBRXRG
SCHEMBL31397430 0.88 FFAR1 (0.41) RXRARXRBPKMPTGS2PPARD
SCHEMBL31397082 0.88 PTGDR2 (0.38) DGAT1SOAT1RXRARXRBRXRG
SCHEMBL31396987 0.86 CTSV (0.35) GRM5PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 — — US disclosed
CN-116194453-A Protein tyrosine phosphatase degrading agent and method of use thereof 卡里科生命科学有限责任公司 2023-05-30 — — CN disclosed
EP-4077319-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-10-26 — — EP disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 — — WO disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 DGAT1 2933/4885SOAT1 1986/4885RXRA 3164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback